Table 13

In this guide

In this guide

- 1. Table 3 Annex A
- 2. Table 4 Annex A
- 3. Table 5 Annex A
- 4. Table 6 Annex A
- 5. Table 7 Annex A
- 6. Table 8 Annex A
- 7. Table 9 Annex A
- 8. Table 10 Annex A
- 9. Table 11 Annex A
- 10. Table 12 Annex A
- 11. Table 13 Annex A
- 12. Table 14 Annex A
- 13. Table 15 Annex A
- 14. Table 16 Annex A
- 15. Table 17 Annex A
- 16. Table 18 Annex A
- 17. Table 19 Annex A
- 18. Table 20 Annex A
- 19. Table 21 Annex A

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

Table 13. Repeated dose toxicity studies for PFCAs - PFDoDA

*Derived by contractor; ** calculated according to EFSA. (2012); NR – not reported; NA – not applicable.

Substance Strain & / CAS no. / species / purity / sex / no. of reference animals	Guideline (GL) study / Good Laboratory Practice (GLP)	(μg/mL / μg/g)	Observed effects at LOAEL (controls vs treated groups). Recovery (controls vs treated groups).
	status		

Published NOAEL /

LOAEL

(mg/kg bw/day) Study

commo

				SD):	
				↑ relative liver weight (%): 2.51 ± 0.14 vs 3.00 ± 0.30#.	
				↑ ALP (IU/L): 357.2 ± 28.6 vs 551.6 ± 95.2 [#]	
		0, 0.1, 0.5 or 2.5.		↓ total cholesterol	
		Corn oil,		(mg/dL): 67.0 ± 9.7 vs 40.6 ±	
	Crl:CD (SD)	Gavage,		7.8 [#] ·	Malaa
PFDoDA	rats.	42 days		Females:	Males:
CAS No.	Male and	(males),		↑	0.1 / 0.5.
not given	female.	41-46 days		albumin/globulin	l
97%.	12/sex/dose	. (females),	NR	ratio: 0.92 vs	Females:
	Recovery:	OECD 422,		0.09 vs 1.13 ± 0.08 [#] ·	
,	5 males and females.	stated.		0.08** 0.1 / 0.5. ↑ relative liver weight (%): 3.23 ± 0.19 vs 3.70	
		Recovery:		$\pm 0.19 \text{ Vs } 3.70$ $\pm 0.22^{\#}$	
		0 or 1,		1 focal pocracio	
		14 days.		↑ focal necrosis: 0 vs 2 (grade 2).	
				Recovery:	
				Data not presented as animals only treated with 200	

Data su that the sensitive organ a histopa change includir hepatohypertr and new were of

Males (mean ±

mg/kg bw/day and not 0.5

mg/kg bw/day

(LOAEL).

The NO repeate toxicity mg/kg

in the I

based of centrilo hypertr hepato

both se 0.5 mg/ bw/day

		0, 1, 5 or 10.	
PFDoDA		Gavage,	
CAS No. 307-55-1	Sprague- Dawley rats.	14 days,	
99%.	Male,	Tween 20,	NR
Zhang et al. (2008)	10/dose.	Non-GL stud,y	
		GLP not stated.	

SEM):	
1 hepatic SOD activity: data only presented in figures.	Males:
↑ mRNA of PPAR-α/g, Acox and CypA4: data only presented in figures.	NA / 1*
Recovery not assessed.	

Rats ex low dos

PFDoA the tred decrease TG and cholest similar seen in PFCAs.

Males (mean \pm